Kimberly E. Fultz

633 total citations
15 papers, 368 citations indexed

About

Kimberly E. Fultz is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Kimberly E. Fultz has authored 15 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Kimberly E. Fultz's work include PI3K/AKT/mTOR signaling in cancer (6 papers), Cancer Mechanisms and Therapy (3 papers) and Amino Acid Enzymes and Metabolism (2 papers). Kimberly E. Fultz is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), Cancer Mechanisms and Therapy (3 papers) and Amino Acid Enzymes and Metabolism (2 papers). Kimberly E. Fultz collaborates with scholars based in United States, Switzerland and Brazil. Kimberly E. Fultz's co-authors include Eugene W. Gerner, Thomas G. O’Brien, Marı́a Elena Martı́nez, Hagit Yerushalmi, David W. Boorman, Yongjun Guo, Naveen Babbar, David S. Alberts, Ning Qu and Janine G. Einspahr and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Kimberly E. Fultz

15 papers receiving 356 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kimberly E. Fultz United States 8 239 84 77 60 56 15 368
José Luís Oliva Spain 15 425 1.8× 101 1.2× 40 0.5× 58 1.0× 95 1.7× 23 596
Simon Chell United Kingdom 7 244 1.0× 145 1.7× 60 0.8× 216 3.6× 100 1.8× 8 531
Prasanna Ekambaram United States 7 208 0.9× 92 1.1× 86 1.1× 85 1.4× 123 2.2× 8 438
Laura González-Santiago Spain 11 228 1.0× 52 0.6× 20 0.3× 41 0.7× 55 1.0× 14 422
Ashok K. Dilly United States 9 187 0.8× 50 0.6× 59 0.8× 37 0.6× 48 0.9× 12 365
Brigitte Simon France 12 194 0.8× 108 1.3× 34 0.4× 23 0.4× 113 2.0× 20 421
Dianren Xia United States 10 314 1.3× 114 1.4× 20 0.3× 76 1.3× 120 2.1× 17 487
Avalon Garcia United States 7 405 1.7× 72 0.9× 41 0.5× 16 0.3× 68 1.2× 7 517
Mandar Deodhar Australia 8 233 1.0× 46 0.5× 35 0.5× 37 0.6× 21 0.4× 14 369

Countries citing papers authored by Kimberly E. Fultz

Since Specialization
Citations

This map shows the geographic impact of Kimberly E. Fultz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly E. Fultz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly E. Fultz more than expected).

Fields of papers citing papers by Kimberly E. Fultz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberly E. Fultz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly E. Fultz. The network helps show where Kimberly E. Fultz may publish in the future.

Co-authorship network of co-authors of Kimberly E. Fultz

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly E. Fultz. A scholar is included among the top collaborators of Kimberly E. Fultz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly E. Fultz. Kimberly E. Fultz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Robinson, Dale, Sogole Bahmanyar, Lida Tehrani, et al.. (2021). Structure-Guided Optimization Provides a Series of TTK Protein Inhibitors with Potent Antitumor Activity. Journal of Medicinal Chemistry. 64(17). 12670–12679. 5 indexed citations
2.
Riggs, Jennifer R., Dale Robinson, Lida Tehrani, et al.. (2019). Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy. Journal of Medicinal Chemistry. 62(9). 4401–4410. 17 indexed citations
3.
Raymon, Heather K., Jason D. Katz, Chunchun Zhao, et al.. (2014). 523 Antitumor activity of mTOR kinase and DNA-PK inhibitor CC-115 in a mouse model of glioblastoma. European Journal of Cancer. 50. 170–170. 1 indexed citations
4.
Mortensen, Deborah S., Kimberly E. Fultz, Matthew Hickman, et al.. (2014). 459 Preclinical characterization of CC-115, a novel inhibitor of DNA-PK and mTOR kinase currently under clinical investigation. European Journal of Cancer. 50. 150–150. 2 indexed citations
5.
Mortensen, Deborah S., John Sapienza, Brandon Whitefield, et al.. (2013). Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. Bioorganic & Medicinal Chemistry Letters. 23(6). 1588–1591. 20 indexed citations
6.
Narla, Rama Krishna, Jason D. Katz, Julius Apuy, et al.. (2013). Abstract A165: Antitumor activity of mTOR kinase inhibitor CC-223 in a mouse model of prostate cancer.. Molecular Cancer Therapeutics. 12(11_Supplement). A165–A165. 1 indexed citations
7.
Mortensen, Deborah S., Kimberly E. Fultz, Matthew Hickman, et al.. (2012). 337 The Discovery and Preclinical Characterization of CC-223, a Novel mTOR Kinase Inhibitor Under Clinical Investigation. European Journal of Cancer. 48. 103–103. 2 indexed citations
8.
Narla, Rama Krishna, Jason D. Katz, Julius Apuy, et al.. (2012). 336 Antitumor Activity of mTOR Kinase Inhibitor CC-223 in a Mouse Model of Glioblastoma. European Journal of Cancer. 48. 103–103. 1 indexed citations
9.
Xu, Shuichan, Toshiya Tsuji, Lisa M. Sapinoso, et al.. (2012). 338 CC-223, a Selective mTOR Kinase Inhibitor, Potently Inhibits Proliferation of a Large Panel of Cancer Cell Lines in Vitro. European Journal of Cancer. 48. 103–103. 1 indexed citations
10.
Mortensen, Deborah S., et al.. (2011). Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(22). 6793–6799. 24 indexed citations
11.
Roy, Upal Kunal Basu, et al.. (2008). Wild‐type APC regulates caveolin‐1 expression in human colon adenocarcinoma cell lines via FOXO1a and C‐myc. Molecular Carcinogenesis. 47(12). 947–955. 27 indexed citations
12.
Ennis, Bruce W., Kimberly E. Fultz, Kevin M. Smith, et al.. (2005). Inhibition of Tumor Growth, Angiogenesis, and Tumor Cell Proliferation by a Small Molecule Inhibitor of c-Jun N-terminal Kinase. Journal of Pharmacology and Experimental Therapeutics. 313(1). 325–332. 57 indexed citations
13.
Martı́nez, Marı́a Elena, Thomas G. O’Brien, Kimberly E. Fultz, et al.. (2003). Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proceedings of the National Academy of Sciences. 100(13). 7859–7864. 147 indexed citations
14.
Fultz, Kimberly E. & Eugene W. Gerner. (2002). APC‐dependent regulation of ornithine decarboxylase in human colon tumor cells. Molecular Carcinogenesis. 34(1). 10–18. 40 indexed citations
15.
Holberg, Catharine J., Robert P. Erickson, Michael Bernas, et al.. (2001). Segregation analyses and a genome-wide linkage search confirm genetic heterogeneity and suggest oligogenic inheritance in some Milroy congenital primary lymphedema families. American Journal of Medical Genetics. 98(4). 303–312. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by José Luís Oliva Breakdown of academic impact, for papers by Simon Chell Breakdown of academic impact, for papers by Prasanna Ekambaram Breakdown of academic impact, for papers by Laura González-Santiago Breakdown of academic impact, for papers by Ashok K. Dilly Breakdown of academic impact, for papers by Brigitte Simon Breakdown of academic impact, for papers by Dianren Xia Breakdown of academic impact, for papers by Avalon Garcia Breakdown of academic impact, for papers by Mandar Deodhar
Rankless by CCL
2026